Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ChemRegen
San Diego, California, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
ChemRegen develops small molecule Wnt and TGF-β pathway inhibitors with preclinical data showing stimulation of cardiomyocyte differentiation from pluripotent stem cells and targeting cancer stem cell pathways to resensitize tumors to therapy[3][4]. Lead candidate ITD-1 targets TGF-β for heart failure; preclinical work on PAWI-2 targets integrin-mediated resistance in pancreatic cancer stem cells.
- Therapeutic areas
- OncologyCardiovascular
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Sanford Burnham Research InstituteHuman BioMolecular Research Institute
Beyond the preview
Go deeper on ChemRegen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChemRegen.